FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285491181> ?p ?o ?g. }

• W4285491181 endingPage "190" @default.
• W4285491181 startingPage "184" @default.
• W4285491181 abstract "In recent years, the standards of drug therapy for advanced kidney cancer have undergone significant changes associated with the appearance of the effective immune checkpoint inhibitors, as well as the high affinity second-generation multi-kinase inhibitors. One of the new tyrosine kinase inhibitors associated with the proven antitumor activity and safety in patients with advanced forms of renal cell carcinoma (RCC) is cabozantinib. The standards of drug therapy for advanced renal cancer have significantly changed in recent years with the emergence of effective anti-tumor immune response checkpoint inhibitors and high-affinity second-generation multikinase inhibitors. One of the novel tyrosine kinase inhibitors with proven antitumor activity and safety in patients with advanced renal cell cancer (RCC) is cabozantinib. In the first-line therapy for advanced renal cancer, the combination of cabozantinib with nivolumab became the regimen of choice in patients of all risk groups, according to International Metastatic RCC Database Consortium (IMDC), regardless of the presence of a sarcomatoid component in the tumor based on the results of the randomized phase III CheckMate 9ER clinical trial (n=651), which demonstrated a significant benefit of immune targeted therapy compared to sunitinib in terms of overall survival (OS; median 37.7 and 34.3 months, respectively), progression-free survival (PFS; median 16.6 and 8.3 months, respectively) and objective response rate (ORR; 55.7 and 28.4%, respectively). Cabozantinib monotherapy in the first-line therapy of advanced renal cancer in patients in the intermediate-risk and poor-risk groups is an alternative regimen reserved for patients with contraindications to anti-tumor immune response checkpoint inhibitors. This recommendation is based on the results of the open-label phase II RCT, CABOSUN (n=157), which showed a significant increase in PFS in the cabozantinib group compared to sunitinib (8.6 month vs 5.3 months, respectively). Also, cabozantinib is the drug of choice in papillary RCC due to the proven advantage in terms of PFS over sunitinib (9.0 and 5.6 months, respectively) demonstrated in the SWOG 1500 phase II RCT (n=152). Cabozantinib remains the drug of choice for second-line therapy of RCC resistant to anti-angiogenic therapy, based on the results of the phase III METEOR RCT, in which the drug showed a compelling advantage over everolimus for PFS (7.4 and 3.8 months, respectively) and OS (21.4 and 16.5 months, respectively). The article presents a detailed analysis of these studies." @default.
• W4285491181 created "2022-07-15" @default.
• W4285491181 creator A5019333966 @default.
• W4285491181 creator A5043821813 @default.
• W4285491181 creator A5061103453 @default.
• W4285491181 date "2022-07-15" @default.
• W4285491181 modified "2023-09-29" @default.
• W4285491181 title "Cabozantinib in the treatment of patients with advanced renal cell carcinoma" @default.
• W4285491181 cites W2045585289 @default.
• W4285491181 cites W2094518946 @default.
• W4285491181 cites W2099752220 @default.
• W4285491181 cites W2100669312 @default.
• W4285491181 cites W2115005218 @default.
• W4285491181 cites W2116949558 @default.
• W4285491181 cites W2118677643 @default.
• W4285491181 cites W2119113195 @default.
• W4285491181 cites W2147864956 @default.
• W4285491181 cites W2153867442 @default.
• W4285491181 cites W2157262448 @default.
• W4285491181 cites W2162424705 @default.
• W4285491181 cites W2173523195 @default.
• W4285491181 cites W2210929914 @default.
• W4285491181 cites W2222086386 @default.
• W4285491181 cites W2415950182 @default.
• W4285491181 cites W2522519290 @default.
• W4285491181 cites W2559918850 @default.
• W4285491181 cites W2762636298 @default.
• W4285491181 cites W2910998423 @default.
• W4285491181 cites W2913745075 @default.
• W4285491181 cites W2933419869 @default.
• W4285491181 cites W2945220204 @default.
• W4285491181 cites W3018979351 @default.
• W4285491181 cites W3038852478 @default.
• W4285491181 cites W3126738486 @default.
• W4285491181 cites W3131063362 @default.
• W4285491181 cites W3133785390 @default.
• W4285491181 cites W3133910751 @default.
• W4285491181 cites W3134178812 @default.
• W4285491181 cites W3135253556 @default.
• W4285491181 cites W3135754868 @default.
• W4285491181 cites W3166432245 @default.
• W4285491181 cites W4212900770 @default.
• W4285491181 cites W4212956164 @default.
• W4285491181 cites W4313248479 @default.
• W4285491181 doi "https://doi.org/10.26442/18151434.2022.2.201704" @default.
• W4285491181 hasPublicationYear "2022" @default.
• W4285491181 type Work @default.
• W4285491181 citedByCount "0" @default.
• W4285491181 crossrefType "journal-article" @default.
• W4285491181 hasAuthorship W4285491181A5019333966 @default.
• W4285491181 hasAuthorship W4285491181A5043821813 @default.
• W4285491181 hasAuthorship W4285491181A5061103453 @default.
• W4285491181 hasBestOaLocation W42854911811 @default.
• W4285491181 hasConcept C121608353 @default.
• W4285491181 hasConcept C126322002 @default.
• W4285491181 hasConcept C143998085 @default.
• W4285491181 hasConcept C2776999253 @default.
• W4285491181 hasConcept C2777472916 @default.
• W4285491181 hasConcept C2777701055 @default.
• W4285491181 hasConcept C2778820342 @default.
• W4285491181 hasConcept C2779490328 @default.
• W4285491181 hasConcept C2780030458 @default.
• W4285491181 hasConcept C2781064419 @default.
• W4285491181 hasConcept C2781068499 @default.
• W4285491181 hasConcept C2781413609 @default.
• W4285491181 hasConcept C71924100 @default.
• W4285491181 hasConceptScore W4285491181C121608353 @default.
• W4285491181 hasConceptScore W4285491181C126322002 @default.
• W4285491181 hasConceptScore W4285491181C143998085 @default.
• W4285491181 hasConceptScore W4285491181C2776999253 @default.
• W4285491181 hasConceptScore W4285491181C2777472916 @default.
• W4285491181 hasConceptScore W4285491181C2777701055 @default.
• W4285491181 hasConceptScore W4285491181C2778820342 @default.
• W4285491181 hasConceptScore W4285491181C2779490328 @default.
• W4285491181 hasConceptScore W4285491181C2780030458 @default.
• W4285491181 hasConceptScore W4285491181C2781064419 @default.
• W4285491181 hasConceptScore W4285491181C2781068499 @default.
• W4285491181 hasConceptScore W4285491181C2781413609 @default.
• W4285491181 hasConceptScore W4285491181C71924100 @default.
• W4285491181 hasIssue "2" @default.
• W4285491181 hasLocation W42854911811 @default.
• W4285491181 hasOpenAccess W4285491181 @default.
• W4285491181 hasPrimaryLocation W42854911811 @default.
• W4285491181 hasRelatedWork W2788498597 @default.
• W4285491181 hasRelatedWork W2792841998 @default.
• W4285491181 hasRelatedWork W2947598588 @default.
• W4285491181 hasRelatedWork W3106854003 @default.
• W4285491181 hasRelatedWork W3134949580 @default.
• W4285491181 hasRelatedWork W3161601890 @default.
• W4285491181 hasRelatedWork W4200316157 @default.
• W4285491181 hasRelatedWork W4212986922 @default.
• W4285491181 hasRelatedWork W4213376619 @default.
• W4285491181 hasRelatedWork W4285598862 @default.
• W4285491181 hasVolume "24" @default.
• W4285491181 isParatext "false" @default.
• W4285491181 isRetracted "false" @default.
• W4285491181 workType "article" @default.